HANDBOOK OF GENERAL MEDICINE VOL 1:@0.076190:0.972666:0.349932:0.972666:0.349932:0.958637:0.076190:0.958637:0.009179:0.009945:0.009945:0.009999:0.007714:0.011679:0.011679:0.007943:0.003723:0.011679:0.006518:0.003723:0.011719:0.007203:0.009945:0.007203:0.008158:0.009945:0.006209:0.003723:0.012351:0.007203:0.009999:0.003037:0.010926:0.003037:0.009945:0.007203:0.003723:0.009434:0.011679:0.006209:0.003723:0.007445
62:@0.083944:0.033217:0.104640:0.033217:0.104640:0.013052:0.083944:0.013052:0.010348:0.010348
TREATMENT AppROACHEs:@0.397030:0.032906:0.624375:0.032906:0.624375:0.013617:0.397030:0.013617:0.007872:0.011217:0.009905:0.013674:0.007872:0.016982:0.009905:0.013674:0.007872:0.005119:0.013674:0.010939:0.010939:0.011217:0.016058:0.013674:0.015023:0.012621:0.009905:0.009202
referenCes:@0.076182:0.489753:0.182620:0.489753:0.182620:0.469589:0.076182:0.469589:0.010718:0.009609:0.008870:0.009609:0.010718:0.009609:0.013674:0.014413:0.009609:0.009609
1. :@0.076190:0.501823:0.089220:0.501823:0.089220:0.489548:0.076190:0.489548:0.006515:0.003257:0.003257
IDF Atlas 2018. :@0.101390:0.501823:0.187680:0.501823:0.187680:0.489548:0.101390:0.489548:0.002658:0.008749:0.005703:0.004480:0.008702:0.003986:0.002352:0.008032:0.004563:0.004480:0.006515:0.006515:0.006515:0.006515:0.003269:0.003257
Diabetes Res Clin Pract. :@0.188903:0.501823:0.330755:0.501823:0.330755:0.489548:0.188903:0.489548:0.008749:0.002352:0.008032:0.008020:0.007644:0.003986:0.007644:0.004563:0.004480:0.007138:0.007644:0.004563:0.004480:0.009560:0.002352:0.002352:0.007173:0.004480:0.006961:0.003540:0.008032:0.007608:0.003986:0.003257:0.003257
2018 Apr;138:271-281. doi: :@0.331978:0.501823:0.484213:0.501823:0.484213:0.489548:0.331978:0.489548:0.006515:0.006515:0.006515:0.006515:0.004492:0.008702:0.008020:0.003540:0.003257:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.006515:0.003257:0.004492:0.008055:0.007702:0.002352:0.003257:0.003257
10.1016/j. diabres.2018.02.023. Epub 2018 Feb 26.:@0.101390:0.512895:0.377874:0.512895:0.377874:0.500620:0.101390:0.500620:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.006515:0.005139:0.002387:0.003257:0.003257:0.008055:0.002352:0.008032:0.008020:0.003540:0.007644:0.004563:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.003257:0.003257:0.006303:0.008020:0.007150:0.008020:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257:0.005703:0.007644:0.008020:0.003257:0.006515:0.006515:0.003257
2. :@0.076190:0.523967:0.089220:0.523967:0.089220:0.511692:0.076190:0.511692:0.006515:0.003257:0.003257
Nissen sE, Wolski K. Effect of rosiglitazone on the risk of myocardial :@0.101390:0.523967:0.484213:0.523967:0.484213:0.511692:0.101390:0.511692:0.008702:0.002352:0.004563:0.004563:0.007644:0.007173:0.003975:0.005856:0.006303:0.003257:0.003975:0.011289:0.007702:0.002352:0.004563:0.005903:0.002352:0.003975:0.006950:0.003257:0.003975:0.006303:0.003692:0.003692:0.007644:0.007608:0.003986:0.003975:0.007702:0.003692:0.003975:0.003540:0.007702:0.004563:0.002352:0.007914:0.002352:0.002352:0.003986:0.008032:0.004998:0.007702:0.007173:0.007644:0.003975:0.007702:0.007173:0.003975:0.003986:0.007173:0.007644:0.003975:0.003540:0.002352:0.004563:0.005903:0.003975:0.007702:0.003692:0.003975:0.011030:0.006303:0.007702:0.007608:0.008032:0.003540:0.008055:0.002352:0.008032:0.002352:0.003257
infarction  and  death  from  cardiovascular  causes. :@0.101390:0.535040:0.395842:0.535040:0.395842:0.522764:0.101390:0.522764:0.002352:0.007173:0.003692:0.008032:0.003540:0.007608:0.003986:0.002352:0.007702:0.007173:0.003257:0.001858:0.008032:0.007173:0.008055:0.003257:0.001858:0.008055:0.007644:0.008032:0.003986:0.007173:0.003257:0.001858:0.003692:0.003540:0.007702:0.011030:0.003257:0.001858:0.007608:0.008032:0.003540:0.008055:0.002352:0.007702:0.006515:0.008032:0.004563:0.007608:0.007150:0.002352:0.008032:0.003540:0.003257:0.001858:0.007608:0.008032:0.007150:0.004563:0.007644:0.004563:0.003257:0.003257
N  Engl  J  Med.:@0.397712:0.535040:0.480932:0.535040:0.480932:0.522764:0.397712:0.522764:0.008702:0.003257:0.001858:0.006303:0.007173:0.007914:0.002352:0.003257:0.001858:0.005668:0.003257:0.001858:0.010807:0.007644:0.008055:0.003257
 :@0.480932:0.535040:0.484189:0.535040:0.484189:0.522764:0.480932:0.522764:0.003257
2007; 356:2457-2471 :@0.101390:0.546112:0.216043:0.546112:0.216043:0.533836:0.101390:0.533836:0.006515:0.006515:0.006515:0.006515:0.003257:0.003257:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.006515:0.006515:0.003257
3. :@0.076190:0.557184:0.088984:0.557184:0.088984:0.544908:0.076190:0.544908:0.006397:0.003140:0.003257
Food and Drug Administration Center for Drug Evaluation and Re-:@0.101390:0.557184:0.481003:0.557184:0.481003:0.544908:0.101390:0.544908:0.005586:0.007585:0.007585:0.007937:0.004633:0.007914:0.007056:0.007937:0.004633:0.008631:0.003422:0.007032:0.007796:0.004633:0.008584:0.007937:0.010913:0.002234:0.007056:0.002234:0.004445:0.003869:0.003422:0.007914:0.003869:0.002234:0.007585:0.007056:0.004633:0.009443:0.007526:0.007056:0.003869:0.007526:0.003422:0.004633:0.003575:0.007585:0.003422:0.004633:0.008631:0.003422:0.007032:0.007796:0.004633:0.006185:0.006397:0.007914:0.002234:0.007032:0.007914:0.003869:0.002234:0.007585:0.007056:0.004633:0.007914:0.007056:0.007937:0.004633:0.007020:0.007526:0.003904
search. Guidance for industry diabetes mellitus – evaluating cardio-:@0.101390:0.568256:0.480944:0.568256:0.480944:0.555980:0.101390:0.555980:0.004445:0.007526:0.007914:0.003422:0.007491:0.007056:0.003140:0.003551:0.010136:0.007032:0.002234:0.007937:0.007914:0.007056:0.007491:0.007526:0.003551:0.003575:0.007585:0.003422:0.003551:0.002234:0.007056:0.007937:0.007032:0.004445:0.003869:0.003422:0.006185:0.003551:0.007937:0.002234:0.007914:0.007902:0.007526:0.003869:0.007526:0.004445:0.003551:0.010913:0.007526:0.002234:0.002234:0.002234:0.003869:0.007032:0.004445:0.003551:0.005762:0.003551:0.007526:0.006397:0.007914:0.002234:0.007032:0.007914:0.003869:0.002234:0.007056:0.007796:0.003551:0.007491:0.007914:0.003422:0.007937:0.002234:0.007585:0.003904
vascular risk in new antidiabetic therapies to treat type 2 diabetes. :@0.101390:0.579328:0.484213:0.579328:0.484213:0.567052:0.101390:0.567052:0.006397:0.007914:0.004445:0.007491:0.007032:0.002234:0.007914:0.003422:0.004069:0.003422:0.002234:0.004445:0.005786:0.004069:0.002234:0.007056:0.004069:0.007056:0.007526:0.009654:0.004069:0.007914:0.007056:0.003869:0.002234:0.007937:0.002234:0.007914:0.007902:0.007526:0.003869:0.002234:0.007491:0.004069:0.003869:0.007056:0.007526:0.003422:0.007914:0.007902:0.002234:0.007526:0.004445:0.004069:0.003869:0.007585:0.004069:0.003869:0.003422:0.007526:0.007914:0.003869:0.004069:0.003869:0.006185:0.007902:0.007526:0.004069:0.006397:0.004069:0.007937:0.002234:0.007914:0.007902:0.007526:0.003869:0.007526:0.004445:0.003257:0.003257
CDER. :@0.101390:0.590400:0.139067:0.590400:0.139067:0.578125:0.101390:0.578125:0.009443:0.008631:0.006185:0.007020:0.003140:0.003257
2008. http://www.fda.gov/downloads/Drugs/GuidanceCom-:@0.138902:0.590400:0.480956:0.590400:0.480956:0.578125:0.138902:0.578125:0.006397:0.006397:0.006397:0.006397:0.003140:0.003093:0.007056:0.003869:0.003869:0.007902:0.003140:0.005021:0.005021:0.009654:0.009654:0.009654:0.003140:0.003575:0.007937:0.007914:0.003140:0.007796:0.007585:0.006397:0.005021:0.007937:0.007585:0.009654:0.007056:0.002234:0.007585:0.007914:0.007937:0.004445:0.005021:0.008631:0.003422:0.007032:0.007796:0.004445:0.005021:0.010136:0.007032:0.002234:0.007937:0.007914:0.007056:0.007491:0.007526:0.009443:0.007585:0.010913:0.003904
plianceRegulatoryInformation/Guidances/ucm071627.pdf :@0.101390:0.601472:0.429638:0.601472:0.429638:0.589197:0.101390:0.589197:0.007902:0.002234:0.002234:0.007914:0.007056:0.007491:0.007526:0.007020:0.007526:0.007796:0.007032:0.002234:0.007914:0.003869:0.007585:0.003422:0.006185:0.002540:0.007056:0.003575:0.007585:0.003422:0.010913:0.007914:0.003869:0.002234:0.007585:0.007056:0.005021:0.010136:0.007032:0.002234:0.007937:0.007914:0.007056:0.007491:0.007526:0.004445:0.005021:0.007032:0.007491:0.010913:0.006397:0.006397:0.006397:0.006397:0.006397:0.006397:0.003140:0.007902:0.007937:0.003692:0.003257
4. :@0.076190:0.612544:0.089220:0.612544:0.089220:0.600269:0.076190:0.600269:0.006515:0.003257:0.003257
Bergenstal  RM, :@0.101390:0.612544:0.190702:0.612544:0.190702:0.600269:0.101390:0.600269:0.006750:0.007644:0.003540:0.007914:0.007644:0.007173:0.004563:0.003986:0.008032:0.002352:0.003257:0.001999:0.007138:0.010807:0.003257:0.003257
et  al. :@0.192713:0.612544:0.226497:0.612544:0.226497:0.600269:0.192713:0.600269:0.007644:0.003986:0.003257:0.001999:0.008032:0.002352:0.003257:0.003257
Type  2 diabetes:  Assessing the  relative risks :@0.228508:0.612544:0.484201:0.612544:0.484201:0.600269:0.228508:0.600269:0.005009:0.006303:0.008020:0.007644:0.003257:0.001999:0.006515:0.005268:0.008055:0.002352:0.008032:0.008020:0.007644:0.003986:0.007644:0.004563:0.003257:0.003257:0.001999:0.008702:0.004563:0.004563:0.007644:0.004563:0.004563:0.002352:0.007173:0.007914:0.005268:0.003986:0.007173:0.007644:0.003257:0.001999:0.003540:0.007644:0.002352:0.008032:0.003986:0.002352:0.006515:0.007644:0.005268:0.003540:0.002352:0.004563:0.005903:0.004563:0.003257
and  benefits  of  glucose-lowering  medications :@0.101390:0.623616:0.377404:0.623616:0.377404:0.611341:0.101390:0.611341:0.008032:0.007173:0.008055:0.003257:0.003140:0.008020:0.007644:0.007173:0.007644:0.002863:0.002863:0.003986:0.004563:0.003257:0.003128:0.007702:0.003692:0.003257:0.003140:0.007914:0.002352:0.007150:0.007608:0.007702:0.004563:0.007644:0.003904:0.002352:0.007702:0.009772:0.007644:0.003540:0.002352:0.007173:0.007914:0.003257:0.003128:0.011030:0.007644:0.008055:0.002352:0.007608:0.008032:0.003986:0.002352:0.007702:0.007173:0.004563:0.003257
Am J Med:@0.380543:0.623616:0.445243:0.623616:0.445243:0.611341:0.380543:0.611341:0.008702:0.011030:0.006397:0.005668:0.006397:0.010807:0.007644:0.008055
. 2010 :@0.445243:0.623616:0.484213:0.623616:0.484213:0.611341:0.445243:0.611341:0.003257:0.006397:0.006515:0.006515:0.006515:0.006515:0.003257
Apr;123(4):374.e9-18. doi:10.1016/j. amjmed.2009.07.017. :@0.101390:0.634688:0.424158:0.634688:0.424158:0.622413:0.101390:0.622413:0.008702:0.008020:0.003540:0.003257:0.006515:0.006515:0.006515:0.004339:0.006515:0.004339:0.003257:0.006515:0.006515:0.006515:0.003257:0.007644:0.006515:0.003904:0.006515:0.006515:0.003257:0.003257:0.008055:0.007702:0.002352:0.003257:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.006515:0.005139:0.002387:0.003257:0.003257:0.008032:0.011030:0.002387:0.011030:0.007644:0.008055:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.003257:0.003257
5. :@0.076190:0.645760:0.089220:0.645760:0.089220:0.633485:0.076190:0.633485:0.006515:0.003257:0.003257
Gerstein HC, Bosch J, Dagenais GR, :@0.101390:0.645760:0.306307:0.645760:0.306307:0.633485:0.101390:0.633485:0.010254:0.007644:0.003540:0.004563:0.003986:0.007644:0.002352:0.007173:0.003163:0.008032:0.009560:0.003257:0.003163:0.006750:0.007702:0.004563:0.007608:0.007173:0.003163:0.005668:0.003257:0.003163:0.008749:0.008032:0.007914:0.007644:0.007173:0.008032:0.002352:0.004563:0.003175:0.010254:0.007138:0.003257:0.003257
et al.:@0.306225:0.645760:0.334659:0.645760:0.334659:0.633485:0.306225:0.633485:0.007644:0.003986:0.003163:0.008032:0.002352:0.003257
 ORIGIN Trial Investigators. :@0.334659:0.645760:0.484201:0.645760:0.484201:0.633485:0.334659:0.633485:0.003163:0.010219:0.007138:0.002658:0.010254:0.002658:0.008702:0.003163:0.005009:0.003540:0.002352:0.008032:0.002352:0.003163:0.002658:0.007173:0.006515:0.007644:0.004563:0.003986:0.002352:0.007914:0.008032:0.003986:0.007702:0.003540:0.004563:0.003257:0.003257
Basal insulin and cardiovascular and other outcomes in dysglyce-:@0.101390:0.656832:0.480944:0.656832:0.480944:0.644557:0.101390:0.644557:0.006750:0.008032:0.004563:0.008032:0.002352:0.004198:0.002352:0.007173:0.004563:0.007150:0.002352:0.002352:0.007173:0.004198:0.008032:0.007173:0.008055:0.004186:0.007608:0.008032:0.003540:0.008055:0.002352:0.007702:0.006515:0.008032:0.004563:0.007608:0.007150:0.002352:0.008032:0.003540:0.004198:0.008032:0.007173:0.008055:0.004186:0.007702:0.003986:0.007173:0.007644:0.003540:0.004175:0.007702:0.007150:0.003986:0.007608:0.007702:0.011030:0.007644:0.004563:0.004186:0.002352:0.007173:0.004186:0.008055:0.006303:0.004563:0.007914:0.002352:0.006303:0.007608:0.007644:0.003904
mia. :@0.101390:0.667905:0.129319:0.667905:0.129319:0.655629:0.101390:0.655629:0.011030:0.002352:0.008032:0.003257:0.003257
N Engl J Med. :@0.129319:0.667905:0.210222:0.667905:0.210222:0.655629:0.129319:0.655629:0.008702:0.003257:0.006303:0.007173:0.007914:0.002352:0.003257:0.005668:0.003257:0.010807:0.007644:0.008055:0.003257:0.003257
2012;367;319-328 :@0.210211:0.667905:0.308577:0.667905:0.308577:0.655629:0.210211:0.655629:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.006515:0.003257
6. :@0.076190:0.678977:0.089220:0.678977:0.089220:0.666701:0.076190:0.666701:0.006515:0.003257:0.003257
Marso  sp,  McGuire  DK,  Zinman B, :@0.101390:0.678977:0.300557:0.678977:0.300557:0.666701:0.101390:0.666701:0.010807:0.008032:0.003540:0.004563:0.007702:0.003257:0.001834:0.005856:0.006961:0.003257:0.003257:0.001834:0.010807:0.007608:0.010254:0.007150:0.002352:0.003540:0.007644:0.003257:0.001834:0.008749:0.006950:0.003257:0.003257:0.001834:0.005644:0.002352:0.007173:0.011030:0.008032:0.007173:0.005104:0.006750:0.003257:0.003257
et  al:@0.302403:0.678977:0.329508:0.678977:0.329508:0.666701:0.302403:0.666701:0.007644:0.003986:0.003257:0.001834:0.008032:0.002352
 for  DEVOTE  study Group. :@0.329508:0.678977:0.484213:0.678977:0.484213:0.666701:0.329508:0.666701:0.005104:0.003692:0.007702:0.003540:0.003257:0.001834:0.008749:0.006303:0.008255:0.010219:0.005009:0.006303:0.003257:0.001846:0.005856:0.003986:0.007150:0.008055:0.006303:0.005104:0.010254:0.003540:0.007702:0.007150:0.008020:0.003257:0.003257
Efficacy and safety of degludec versus glargine in type 2 diabe:@0.101390:0.690049:0.477040:0.690049:0.477040:0.677773:0.101390:0.677773:0.006303:0.003692:0.002863:0.002863:0.007608:0.008032:0.007608:0.006303:0.004810:0.008032:0.007173:0.008055:0.004810:0.004563:0.008032:0.003692:0.007644:0.003986:0.006303:0.004810:0.007702:0.003692:0.004810:0.008055:0.007644:0.007914:0.002352:0.007150:0.008055:0.007644:0.007608:0.004810:0.006515:0.007644:0.003540:0.004563:0.007150:0.004563:0.004810:0.007914:0.002352:0.008032:0.003540:0.007914:0.002352:0.007173:0.007644:0.004810:0.002352:0.007173:0.004810:0.003986:0.006303:0.008020:0.007644:0.004810:0.006515:0.004810:0.008055:0.002352:0.008032:0.008020:0.007644
-:@0.477040:0.690049:0.480944:0.690049:0.480944:0.677773:0.477040:0.677773:0.003904
tes. :@0.101390:0.701121:0.124098:0.701121:0.124098:0.688845:0.101390:0.688845:0.003986:0.007644:0.004563:0.003257:0.003257
N  Engl J Med. :@0.126214:0.701121:0.213491:0.701121:0.213491:0.688845:0.126214:0.688845:0.008702:0.003257:0.002117:0.006303:0.007173:0.007914:0.002352:0.005386:0.005668:0.005386:0.010807:0.007644:0.008055:0.003257:0.003257
2017 Aug  24;377(8):723-732.  doi:  10.1056/NEJ-:@0.215620:0.701121:0.480944:0.701121:0.480944:0.688845:0.215620:0.688845:0.006515:0.006515:0.006515:0.006515:0.005386:0.008702:0.007150:0.007914:0.003257:0.002117:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.004339:0.006515:0.004339:0.003257:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.006515:0.003257:0.003257:0.002152:0.008055:0.007702:0.002352:0.003257:0.003257:0.002117:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.006515:0.005139:0.008702:0.006303:0.005668:0.003904
Moa1615692. Epub 2017 Jun 12. :@0.101390:0.712193:0.284905:0.712193:0.284905:0.699918:0.101390:0.699918:0.010807:0.007702:0.008032:0.006515:0.006515:0.006515:0.006515:0.006515:0.006515:0.006515:0.003257:0.003257:0.006303:0.008020:0.007150:0.008020:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257:0.005668:0.007150:0.007173:0.003257:0.006515:0.006515:0.003257:0.003257
7. :@0.076190:0.723265:0.089220:0.723265:0.089220:0.710990:0.076190:0.710990:0.006515:0.003257:0.003257
scirica BM, Bhatt  DL, Braunwald E, :@0.101390:0.723265:0.306683:0.723265:0.306683:0.710990:0.101390:0.710990:0.005856:0.007608:0.002352:0.003540:0.002352:0.007608:0.008032:0.005221:0.006750:0.010807:0.003257:0.005221:0.006750:0.007173:0.008032:0.003986:0.003986:0.003257:0.001952:0.008749:0.005433:0.003257:0.005221:0.006750:0.003540:0.008032:0.007150:0.007173:0.009772:0.008032:0.002352:0.008055:0.005221:0.006303:0.003257:0.003257
et  al.:@0.308647:0.723265:0.339127:0.723265:0.339127:0.710990:0.308647:0.710990:0.007644:0.003986:0.003257:0.001952:0.008032:0.002352:0.003257
  saxagliptin and cardio-:@0.339127:0.723265:0.480956:0.723265:0.480956:0.710990:0.339127:0.710990:0.003257:0.001964:0.005856:0.008032:0.005644:0.008032:0.007914:0.002352:0.002352:0.008020:0.003986:0.002352:0.007173:0.005221:0.008032:0.007173:0.008055:0.005221:0.007608:0.008032:0.003540:0.008055:0.002352:0.007702:0.003904
vascular outcomes in patients with type 2 diabetes mellitus. :@0.101390:0.734337:0.444584:0.734337:0.444584:0.722062:0.101390:0.722062:0.006515:0.008032:0.004563:0.007608:0.007150:0.002352:0.008032:0.003540:0.003598:0.007702:0.007150:0.003986:0.007608:0.007702:0.011030:0.007644:0.004563:0.003598:0.002352:0.007173:0.003587:0.008020:0.008032:0.003986:0.002352:0.007644:0.007173:0.003986:0.004563:0.003598:0.009772:0.002352:0.003986:0.007173:0.003587:0.003986:0.006303:0.008020:0.007644:0.003587:0.006515:0.003598:0.008055:0.002352:0.008032:0.008020:0.007644:0.003986:0.007644:0.004563:0.003598:0.011030:0.007644:0.002352:0.002352:0.002352:0.003986:0.007150:0.004563:0.003257:0.003257
N Engl :@0.444925:0.734337:0.484213:0.734337:0.484213:0.722062:0.444925:0.722062:0.008702:0.003587:0.006303:0.007173:0.007914:0.002352:0.003257
J Med.:@0.101390:0.745409:0.140078:0.745409:0.140078:0.733134:0.101390:0.733134:0.005668:0.003257:0.010807:0.007644:0.008055:0.003257
 2013;369:1317–26 :@0.140078:0.745409:0.243677:0.745409:0.243677:0.733134:0.140078:0.733134:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.006515:0.005880:0.006515:0.006515:0.003257
8. :@0.076190:0.756481:0.089220:0.756481:0.089220:0.744206:0.076190:0.744206:0.006515:0.003257:0.003257
Green  JB, Bethel MA,  Armstrong  pW, :@0.101390:0.756481:0.328026:0.756481:0.328026:0.744206:0.101390:0.744206:0.010254:0.003540:0.007644:0.007644:0.007173:0.003257:0.003434:0.005668:0.006750:0.003257:0.006703:0.006750:0.007644:0.003986:0.007173:0.007644:0.002352:0.006703:0.010807:0.008702:0.003257:0.003257:0.003434:0.008702:0.003540:0.011030:0.004563:0.003986:0.003540:0.007702:0.007173:0.007902:0.003257:0.003445:0.006961:0.011289:0.003257:0.003257
et al.:@0.331472:0.756481:0.363445:0.756481:0.363445:0.744206:0.331472:0.744206:0.007644:0.003986:0.006703:0.008032:0.002352:0.003257
 Effect of sitagliptin :@0.363445:0.756481:0.484213:0.756481:0.484213:0.744206:0.363445:0.744206:0.006703:0.006303:0.003692:0.003692:0.007644:0.007608:0.003986:0.006703:0.007702:0.003692:0.006703:0.004563:0.002352:0.003986:0.008032:0.007914:0.002352:0.002352:0.008020:0.003986:0.002352:0.007173:0.003257
on cardiovascular  outcomes  in type 2 diabetes. :@0.101390:0.767553:0.392808:0.767553:0.392808:0.755278:0.101390:0.755278:0.007702:0.007173:0.005880:0.007608:0.008032:0.003540:0.008055:0.002352:0.007702:0.006515:0.008032:0.004563:0.007608:0.007150:0.002352:0.008032:0.003540:0.003257:0.002634:0.007702:0.007150:0.003986:0.007608:0.007702:0.011030:0.007644:0.004563:0.003257:0.002611:0.002352:0.007173:0.005880:0.003986:0.006303:0.008020:0.007644:0.005880:0.006515:0.005880:0.008055:0.002352:0.008032:0.008020:0.007644:0.003986:0.007644:0.004563:0.003257:0.003257
N Engl J Med.:@0.395431:0.767553:0.480944:0.767553:0.480944:0.755278:0.395431:0.755278:0.008702:0.005880:0.006303:0.007173:0.007914:0.002352:0.005880:0.005668:0.005880:0.010807:0.007644:0.008055:0.003257
 :@0.480944:0.767553:0.484201:0.767553:0.484201:0.755278:0.480944:0.755278:0.003257
2015;373:232-42 :@0.101390:0.778625:0.193242:0.778625:0.193242:0.766350:0.101390:0.766350:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.003257
9. :@0.076190:0.789697:0.089220:0.789697:0.089220:0.777422:0.076190:0.777422:0.006515:0.003257:0.003257
White WB, Cannon Cp, Heller sR, :@0.101390:0.789697:0.295148:0.789697:0.295148:0.777422:0.101390:0.777422:0.011289:0.007173:0.002352:0.003986:0.007644:0.004469:0.011289:0.006750:0.003257:0.004469:0.009560:0.008032:0.007173:0.007173:0.007702:0.007173:0.004469:0.009560:0.006961:0.003257:0.004469:0.008032:0.007644:0.002352:0.002352:0.007644:0.003540:0.004480:0.005856:0.007138:0.003257:0.003257
et al.:@0.296359:0.789697:0.326098:0.789697:0.326098:0.777422:0.296359:0.777422:0.007644:0.003986:0.004469:0.008032:0.002352:0.003257
 Alogliptin after acute cor-:@0.326098:0.789697:0.480956:0.789697:0.480956:0.777422:0.326098:0.777422:0.004469:0.008702:0.002352:0.007702:0.007914:0.002352:0.002352:0.008020:0.003986:0.002352:0.007173:0.004469:0.008032:0.003692:0.003986:0.007644:0.003540:0.004469:0.008032:0.007608:0.007150:0.003986:0.007644:0.004469:0.007608:0.007702:0.003551:0.003904
onary syndrome in patients with type 2 diabetes. :@0.101390:0.800770:0.395113:0.800770:0.395113:0.788494:0.101390:0.788494:0.007702:0.007173:0.008032:0.003540:0.006303:0.005303:0.004563:0.006303:0.007173:0.008055:0.003540:0.007702:0.011030:0.007644:0.005303:0.002352:0.007173:0.005303:0.008020:0.008032:0.003986:0.002352:0.007644:0.007173:0.003986:0.004563:0.005303:0.009772:0.002352:0.003986:0.007173:0.005303:0.003986:0.006303:0.008020:0.007644:0.005303:0.006515:0.005303:0.008055:0.002352:0.008032:0.008020:0.007644:0.003986:0.007644:0.004563:0.003257:0.003257
N Engl J Med.:@0.397159:0.800770:0.480944:0.800770:0.480944:0.788494:0.397159:0.788494:0.008702:0.005303:0.006303:0.007173:0.007914:0.002352:0.005303:0.005668:0.005303:0.010807:0.007644:0.008055:0.003257
 :@0.480944:0.800770:0.484201:0.800770:0.484201:0.788494:0.480944:0.788494:0.003257
2013;369:1327-35 :@0.101390:0.811842:0.199757:0.811842:0.199757:0.799566:0.101390:0.799566:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.003257
10.  Rosenstock  J,  perkovic V, Alexander  JH, :@0.076190:0.822914:0.339292:0.822914:0.339292:0.810638:0.076190:0.810638:0.006515:0.006515:0.003257:0.003257:0.005656:0.007138:0.007702:0.004563:0.007644:0.007173:0.004563:0.003986:0.007702:0.007608:0.005903:0.003257:0.001987:0.005668:0.003257:0.003257:0.001999:0.006961:0.007644:0.003540:0.005903:0.007702:0.006515:0.002352:0.007608:0.005256:0.008255:0.003257:0.005256:0.008702:0.002352:0.007644:0.005644:0.008032:0.007173:0.008055:0.007644:0.003540:0.003257:0.001987:0.005668:0.008032:0.003257:0.003257
et al. :@0.341291:0.822914:0.375075:0.822914:0.375075:0.810638:0.341291:0.810638:0.007644:0.003986:0.005256:0.008032:0.002352:0.003257:0.003257
Rationale, design, :@0.377074:0.822914:0.484213:0.822914:0.484213:0.810638:0.377074:0.810638:0.007138:0.008032:0.003986:0.002352:0.007702:0.007173:0.008032:0.002352:0.007644:0.003257:0.005256:0.008055:0.007644:0.004563:0.002352:0.007914:0.007173:0.003257:0.003257
and baseline characteristics of the CArdiovascular safety and Re-:@0.101390:0.833986:0.480956:0.833986:0.480956:0.821710:0.101390:0.821710:0.008032:0.007173:0.008055:0.003986:0.008020:0.008032:0.004563:0.007644:0.002352:0.002352:0.007173:0.007644:0.003986:0.007608:0.007173:0.008032:0.003540:0.008032:0.007608:0.003986:0.007644:0.003540:0.002352:0.004563:0.003986:0.002352:0.007608:0.004563:0.003986:0.007702:0.003692:0.003986:0.003986:0.007173:0.007644:0.003975:0.009560:0.008702:0.003540:0.008055:0.002352:0.007702:0.006515:0.008032:0.004563:0.007608:0.007150:0.002352:0.008032:0.003540:0.003986:0.004563:0.008032:0.003692:0.007644:0.003986:0.006303:0.003986:0.008032:0.007173:0.008055:0.003986:0.007138:0.007644:0.003904
nal Microvascular outcomE study with LINAgliptin (CARMELINA®): :@0.101390:0.845058:0.484225:0.845058:0.484225:0.832783:0.101390:0.832783:0.007173:0.008032:0.002352:0.004845:0.010807:0.002352:0.007608:0.003540:0.007702:0.006515:0.008032:0.004563:0.007608:0.007150:0.002352:0.008032:0.003540:0.004845:0.007702:0.007150:0.003986:0.007608:0.007702:0.011030:0.006303:0.004833:0.004563:0.003986:0.007150:0.008055:0.006303:0.004845:0.009772:0.002352:0.003986:0.007173:0.004833:0.005433:0.002658:0.008702:0.008702:0.007914:0.002352:0.002352:0.008020:0.003986:0.002352:0.007173:0.004833:0.004339:0.009560:0.008702:0.007138:0.010807:0.006303:0.005433:0.002658:0.008702:0.008702:0.008784:0.004339:0.003257:0.003257
A randomized, double-blind, placebo-controlled clinical  trial in :@0.101390:0.856130:0.484225:0.856130:0.484225:0.843855:0.101390:0.843855:0.008702:0.006997:0.003540:0.008032:0.007173:0.008055:0.007702:0.011030:0.002352:0.004998:0.007644:0.008055:0.003257:0.006997:0.008055:0.007702:0.007150:0.008020:0.002352:0.007644:0.003904:0.008020:0.002352:0.002352:0.007173:0.008055:0.003257:0.006997:0.008020:0.002352:0.008032:0.007608:0.007644:0.008020:0.007702:0.003904:0.007608:0.007702:0.007173:0.003986:0.003540:0.007702:0.002352:0.002352:0.007644:0.008055:0.006997:0.007608:0.002352:0.002352:0.007173:0.002352:0.007608:0.008032:0.002352:0.003257:0.003751:0.003986:0.003540:0.002352:0.008032:0.002352:0.006997:0.002352:0.007173:0.003257
patients with type 2 diabetes and high cardio-renal risk. :@0.101390:0.867202:0.435824:0.867202:0.435824:0.854927:0.101390:0.854927:0.008020:0.008032:0.003986:0.002352:0.007644:0.007173:0.003986:0.004563:0.005245:0.009772:0.002352:0.003986:0.007173:0.005245:0.003986:0.006303:0.008020:0.007644:0.005245:0.006515:0.005245:0.008055:0.002352:0.008032:0.008020:0.007644:0.003986:0.007644:0.004563:0.005245:0.008032:0.007173:0.008055:0.005245:0.007173:0.002352:0.007914:0.007173:0.005245:0.007608:0.008032:0.003540:0.008055:0.002352:0.007702:0.003904:0.003540:0.007644:0.007173:0.008032:0.002352:0.005245:0.003540:0.002352:0.004563:0.005903:0.003257:0.003257
Cardio-:@0.437811:0.867202:0.480956:0.867202:0.480956:0.854927:0.437811:0.854927:0.009560:0.008032:0.003540:0.008055:0.002352:0.007702:0.003904
vascular Diabetology, :@0.101390:0.878274:0.229707:0.878274:0.229707:0.865999:0.101390:0.865999:0.006515:0.008032:0.004563:0.007608:0.007150:0.002352:0.008032:0.003540:0.003257:0.008749:0.002352:0.008032:0.008020:0.007644:0.003986:0.007702:0.002352:0.007702:0.007914:0.006303:0.003257:0.003257
2018;17:39. :@0.229707:0.878274:0.294854:0.878274:0.294854:0.865999:0.229707:0.865999:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.003257:0.006515:0.006515:0.003257:0.003257
11.  Davidson JA. Advances in therapy for type 2 diabetes: GLp-1 re-:@0.076190:0.889346:0.480944:0.889346:0.480944:0.877071:0.076190:0.877071:0.006515:0.006515:0.003257:0.003257:0.005656:0.008749:0.008032:0.006515:0.002352:0.008055:0.004563:0.007702:0.007173:0.004727:0.005668:0.008702:0.003257:0.004715:0.008702:0.008055:0.006515:0.008032:0.007173:0.007608:0.007644:0.004563:0.004715:0.002352:0.007173:0.004715:0.003986:0.007173:0.007644:0.003540:0.008032:0.008020:0.006303:0.004715:0.003692:0.007702:0.003540:0.004715:0.003986:0.006303:0.008020:0.007644:0.004715:0.006515:0.004715:0.008055:0.002352:0.008032:0.008020:0.007644:0.003986:0.007644:0.004563:0.003257:0.004715:0.010254:0.005433:0.006961:0.003904:0.006515:0.004715:0.003540:0.007644:0.003904
ceptor agonists and Dpp-4 inhibitors. :@0.101390:0.900418:0.308788:0.900418:0.308788:0.888143:0.101390:0.888143:0.007608:0.007644:0.008020:0.003986:0.007702:0.003540:0.002634:0.008032:0.007914:0.007702:0.007173:0.002352:0.004563:0.003986:0.004563:0.002634:0.008032:0.007173:0.008055:0.002634:0.008749:0.006961:0.006961:0.003904:0.006515:0.002634:0.002352:0.007173:0.007173:0.002352:0.008020:0.002352:0.003986:0.007702:0.003540:0.004563:0.003257:0.003257
Cleve Clin J Med. :@0.308189:0.900418:0.409953:0.900418:0.409953:0.888143:0.308189:0.888143:0.009560:0.002352:0.007644:0.006515:0.007644:0.002646:0.009560:0.002352:0.002352:0.007173:0.002646:0.005668:0.002634:0.010807:0.007644:0.008055:0.003257:0.003257
2009;76(sup-:@0.409330:0.900418:0.480956:0.900418:0.480956:0.888143:0.409330:0.888143:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.004339:0.005856:0.007150:0.008032:0.003904
pl. 5):s28-s38 [pubMed]. :@0.101390:0.911490:0.240738:0.911490:0.240738:0.899215:0.101390:0.899215:0.008020:0.002352:0.003257:0.003257:0.006515:0.004339:0.003257:0.005856:0.006515:0.006515:0.003904:0.005856:0.006515:0.006515:0.003257:0.004139:0.006961:0.007150:0.008020:0.010807:0.007644:0.008055:0.004127:0.003257:0.003257
12.  Amori RE, Lau J, pittas AG,:@0.076190:0.922562:0.248581:0.922562:0.248581:0.910287:0.076190:0.910287:0.006515:0.006515:0.003257:0.003257:0.005656:0.008702:0.011030:0.007702:0.003540:0.002352:0.003104:0.007138:0.006303:0.003257:0.003104:0.005433:0.008032:0.007150:0.003104:0.005668:0.003257:0.003116:0.006961:0.002352:0.003986:0.003986:0.008032:0.004563:0.003104:0.008702:0.010254:0.003257
 et al.:@0.248581:0.922562:0.280072:0.922562:0.280072:0.910287:0.248581:0.910287:0.003116:0.007644:0.003986:0.003104:0.008032:0.002352:0.003257
 Efficacy and safety of incretin ther:@0.280072:0.922562:0.477040:0.922562:0.477040:0.910287:0.280072:0.910287:0.003104:0.006303:0.003692:0.002863:0.002863:0.007608:0.008032:0.007608:0.006303:0.003116:0.008032:0.007173:0.008055:0.003104:0.004563:0.008032:0.003692:0.007644:0.003986:0.006303:0.003116:0.007702:0.003692:0.003104:0.002352:0.007173:0.007608:0.003540:0.007644:0.003986:0.002352:0.007173:0.003104:0.003986:0.007173:0.007644:0.003540
-:@0.477051:0.922562:0.480956:0.922562:0.480956:0.910287:0.477051:0.910287:0.003904
apy in type 2 diabetes: systematic review and meta-analysis. :@0.101390:0.933635:0.447595:0.933635:0.447595:0.921359:0.101390:0.921359:0.008032:0.008020:0.006303:0.002728:0.002352:0.007173:0.002716:0.003986:0.006303:0.008020:0.007644:0.002716:0.006515:0.002716:0.008055:0.002352:0.008032:0.008020:0.007644:0.003986:0.007644:0.004563:0.003257:0.002716:0.005856:0.006303:0.004563:0.003986:0.007644:0.011030:0.008032:0.003986:0.002352:0.007608:0.002716:0.003540:0.007644:0.006515:0.002352:0.007644:0.009772:0.002716:0.008032:0.007173:0.008055:0.002716:0.011030:0.007644:0.003986:0.008032:0.003904:0.008032:0.007173:0.008032:0.002352:0.006303:0.004563:0.002352:0.004563:0.003257:0.003257
JAMA:@0.447077:0.933635:0.480956:0.933635:0.480956:0.921359:0.447077:0.921359:0.005668:0.008702:0.010807:0.008702
 :@0.480944:0.933635:0.484201:0.933635:0.484201:0.921359:0.480944:0.921359:0.003257
2007;298:194-206 [pubMed]. :@0.101379:0.944707:0.263174:0.944707:0.263174:0.932431:0.101379:0.932431:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.006515:0.003257:0.004151:0.006961:0.007150:0.008020:0.010807:0.007644:0.008055:0.004127:0.003257:0.003257
13.  Neal B, perkovic V, Mahaffrey KW, :@0.519032:0.484474:0.744175:0.484474:0.744175:0.472199:0.519032:0.472199:0.006515:0.006515:0.003257:0.003257:0.005656:0.008702:0.007644:0.008032:0.002352:0.003963:0.006750:0.003257:0.003963:0.006961:0.007644:0.003540:0.005903:0.007702:0.006503:0.002352:0.007608:0.003963:0.008255:0.003257:0.003963:0.010807:0.008032:0.007173:0.008032:0.003692:0.003692:0.003540:0.007644:0.006303:0.003963:0.006950:0.011289:0.003257:0.003257
et al. :@0.744880:0.484474:0.777371:0.484474:0.777371:0.472199:0.744880:0.472199:0.007644:0.003986:0.003963:0.008032:0.002352:0.003257:0.003257
Canagliflozin and cardio:@0.778077:0.484474:0.919893:0.484474:0.919893:0.472199:0.778077:0.472199:0.009560:0.008032:0.007173:0.008032:0.007914:0.002352:0.002352:0.002852:0.002852:0.007702:0.004998:0.002352:0.007173:0.003963:0.008032:0.007173:0.008055:0.003963:0.007608:0.008032:0.003540:0.008055:0.002352:0.007702
-:@0.919893:0.484474:0.923797:0.484474:0.923797:0.472199:0.919893:0.472199:0.003904
vascular and renal events in type 2 diabetes. :@0.544232:0.495376:0.809239:0.495376:0.809239:0.483100:0.544232:0.483100:0.006515:0.008032:0.004563:0.007608:0.007150:0.002352:0.008032:0.003540:0.004127:0.008032:0.007173:0.008055:0.004127:0.003540:0.007644:0.007173:0.008032:0.002352:0.004127:0.007644:0.006515:0.007644:0.007173:0.003986:0.004563:0.004127:0.002352:0.007173:0.004127:0.003986:0.006303:0.008020:0.007644:0.004127:0.006515:0.004127:0.008055:0.002352:0.008032:0.008020:0.007644:0.003986:0.007644:0.004563:0.003257:0.003257
N Engl J Med. :@0.810109:0.495376:0.893611:0.495376:0.893611:0.483100:0.810109:0.483100:0.008702:0.004116:0.006303:0.007173:0.007914:0.002352:0.004127:0.005668:0.004127:0.010807:0.007644:0.008055:0.003257:0.003257
2017; :@0.894481:0.495376:0.927055:0.495376:0.927055:0.483100:0.894481:0.483100:0.006515:0.006515:0.006515:0.006515:0.003257:0.003257
377:644-657:@0.544232:0.506277:0.610025:0.506277:0.610025:0.494002:0.544232:0.494002:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.006515
14.  Wiviott sD, Raz I, Bonaca Mp, :@0.519032:0.517179:0.707991:0.517179:0.707991:0.504903:0.519032:0.504903:0.006515:0.006515:0.003257:0.003257:0.005656:0.011289:0.002352:0.006515:0.002352:0.007702:0.003986:0.003986:0.002411:0.005856:0.008749:0.003257:0.002411:0.007138:0.008032:0.004998:0.002411:0.002658:0.003257:0.002411:0.006750:0.007702:0.007173:0.008032:0.007608:0.008032:0.002411:0.010807:0.006961:0.003257:0.003257
et al.:@0.707145:0.517179:0.734826:0.517179:0.734826:0.504903:0.707145:0.504903:0.007644:0.003986:0.002411:0.008032:0.002352:0.003257
 Dapagliflozin and cardiovascular :@0.734826:0.517179:0.927031:0.517179:0.927031:0.504903:0.734826:0.504903:0.002411:0.008749:0.008032:0.008020:0.008032:0.007914:0.002352:0.002352:0.002852:0.002852:0.007702:0.004998:0.002352:0.007173:0.002411:0.008032:0.007173:0.008055:0.002411:0.007608:0.008032:0.003540:0.008055:0.002352:0.007702:0.006515:0.008032:0.004563:0.007608:0.007150:0.002352:0.008032:0.003540:0.003257
outcomes in type 2 diabetes. :@0.544232:0.528080:0.713448:0.528080:0.713448:0.515805:0.544232:0.515805:0.007702:0.007150:0.003986:0.007608:0.007702:0.011030:0.007644:0.004563:0.003257:0.002352:0.007173:0.003257:0.003986:0.006303:0.008020:0.007644:0.003257:0.006515:0.003257:0.008055:0.002352:0.008032:0.008020:0.007644:0.003986:0.007644:0.004563:0.003257:0.003257
N Engl J Med.:@0.713436:0.528080:0.791082:0.528080:0.791082:0.515805:0.713436:0.515805:0.008702:0.003257:0.006303:0.007173:0.007914:0.002352:0.003257:0.005668:0.003257:0.010807:0.007644:0.008055:0.003257
 2019;380:347-357:@0.791071:0.528080:0.889437:0.528080:0.889437:0.515805:0.791071:0.515805:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.006515
15.  pfeffer MA, Claggett B, Diaz R, :@0.519032:0.538982:0.727994:0.538982:0.727994:0.526706:0.519032:0.526706:0.006515:0.006515:0.003257:0.003257:0.005656:0.006961:0.003692:0.007644:0.003692:0.003692:0.007644:0.003540:0.004986:0.010807:0.008702:0.003257:0.004986:0.009560:0.002352:0.008032:0.007914:0.007914:0.007644:0.003986:0.003986:0.004986:0.006750:0.003257:0.004998:0.008749:0.002352:0.008032:0.004998:0.004998:0.007138:0.003257:0.003257
et al.:@0.729734:0.538982:0.760003:0.538982:0.760003:0.526706:0.729734:0.526706:0.007644:0.003986:0.004998:0.008032:0.002352:0.003257
 Lixisenatide in patients with :@0.760003:0.538982:0.927043:0.538982:0.927043:0.526706:0.760003:0.526706:0.004998:0.005433:0.002352:0.005644:0.002352:0.004563:0.007644:0.007173:0.008032:0.003986:0.002352:0.008055:0.007644:0.004998:0.002352:0.007173:0.004998:0.008020:0.008032:0.003986:0.002352:0.007644:0.007173:0.003986:0.004563:0.004998:0.009772:0.002352:0.003986:0.007173:0.003257
type 2 diabetes and acute  coronary  syndrome. :@0.544232:0.549883:0.835038:0.549883:0.835038:0.537608:0.544232:0.537608:0.003986:0.006303:0.008020:0.007644:0.006044:0.006515:0.006044:0.008055:0.002352:0.008032:0.008020:0.007644:0.003986:0.007644:0.004563:0.006044:0.008032:0.007173:0.008055:0.006044:0.008032:0.007608:0.007150:0.003986:0.007644:0.003257:0.002775:0.007608:0.007702:0.003540:0.007702:0.007173:0.008032:0.003540:0.006303:0.003257:0.002775:0.004563:0.006303:0.007173:0.008055:0.003540:0.007702:0.011030:0.007644:0.003257:0.003257
N  Engl J Med.:@0.837802:0.549883:0.923797:0.549883:0.923797:0.537608:0.837802:0.537608:0.008702:0.003257:0.002775:0.006303:0.007173:0.007914:0.002352:0.006044:0.005668:0.006044:0.010807:0.007644:0.008055:0.003257
 :@0.923797:0.549883:0.927055:0.549883:0.927055:0.537608:0.923797:0.537608:0.003257
2015;373:2247-2257:@0.544232:0.560785:0.652370:0.560785:0.652370:0.548509:0.544232:0.548509:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.006515:0.006515
16.  Marso  sp,  Daniels GH, Brown-Frandsen  K, :@0.519032:0.571686:0.793857:0.571686:0.793857:0.559411:0.519032:0.559411:0.006515:0.006515:0.003257:0.003257:0.005656:0.010807:0.008032:0.003540:0.004563:0.007702:0.003257:0.003210:0.005856:0.006961:0.003257:0.003257:0.003199:0.008749:0.008032:0.007173:0.002352:0.007644:0.002352:0.004563:0.006468:0.010254:0.008032:0.003257:0.006468:0.006750:0.003540:0.007702:0.009772:0.007173:0.003904:0.005703:0.003540:0.008032:0.007173:0.008055:0.004563:0.007644:0.007173:0.003257:0.003199:0.006950:0.003257:0.003257
et  al.:@0.797068:0.571686:0.828794:0.571686:0.828794:0.559411:0.797068:0.559411:0.007644:0.003986:0.003257:0.003199:0.008032:0.002352:0.003257
 Liraglutide and :@0.828794:0.571686:0.927055:0.571686:0.927055:0.559411:0.828794:0.559411:0.006468:0.005433:0.002352:0.003540:0.008032:0.007914:0.002352:0.007150:0.003986:0.002352:0.008055:0.007644:0.006468:0.008032:0.007173:0.008055:0.003257
cardiovascular  outcomes in type 2 diabetes. :@0.544232:0.582588:0.826431:0.582588:0.826431:0.570312:0.544232:0.570312:0.007608:0.008032:0.003540:0.008055:0.002352:0.007702:0.006515:0.008032:0.004563:0.007608:0.007150:0.002352:0.008032:0.003540:0.003257:0.004939:0.007702:0.007150:0.003986:0.007608:0.007702:0.011030:0.007644:0.004563:0.008184:0.002352:0.007173:0.008184:0.003986:0.006303:0.008020:0.007644:0.008184:0.006515:0.008184:0.008055:0.002352:0.008032:0.008020:0.007644:0.003986:0.007644:0.004563:0.003257:0.003257
N Engl J Med.:@0.831358:0.582588:0.923785:0.582588:0.923785:0.570312:0.831358:0.570312:0.008702:0.008184:0.006303:0.007173:0.007914:0.002352:0.008184:0.005668:0.008184:0.010807:0.007644:0.008055:0.003257
 :@0.923785:0.582588:0.927043:0.582588:0.927043:0.570312:0.923785:0.570312:0.003257
2016;375:311-322 :@0.544232:0.593489:0.642598:0.593489:0.642598:0.581214:0.544232:0.581214:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.006515:0.003257
17.  Marso sp, Bain sC, Consoli A, :@0.519032:0.604390:0.707980:0.604390:0.707980:0.592115:0.519032:0.592115:0.006515:0.006515:0.003257:0.003257:0.005656:0.010807:0.008032:0.003540:0.004563:0.007702:0.002681:0.005856:0.006961:0.003257:0.002681:0.006750:0.008032:0.002352:0.007173:0.002693:0.005856:0.009560:0.003257:0.002681:0.009560:0.007702:0.007173:0.004563:0.007702:0.002352:0.002352:0.002693:0.008702:0.003257:0.003257
et al. :@0.707415:0.604390:0.738624:0.604390:0.738624:0.592115:0.707415:0.592115:0.007644:0.003986:0.002681:0.008032:0.002352:0.003257:0.003257
semaglutide and cardiovascular :@0.738060:0.604390:0.927055:0.604390:0.927055:0.592115:0.738060:0.592115:0.005856:0.007644:0.011030:0.008032:0.007914:0.002352:0.007150:0.003986:0.002352:0.008055:0.007644:0.002693:0.008032:0.007173:0.008055:0.002693:0.007608:0.008032:0.003540:0.008055:0.002352:0.007702:0.006515:0.008032:0.004563:0.007608:0.007150:0.002352:0.008032:0.003540:0.003257
outcomes  in patients with type 2 diabetes. :@0.544232:0.615292:0.802395:0.615292:0.802395:0.603017:0.544232:0.603017:0.007702:0.007150:0.003986:0.007608:0.007702:0.011030:0.007644:0.004563:0.003257:0.002222:0.002352:0.007173:0.005492:0.008020:0.008032:0.003986:0.002352:0.007644:0.007173:0.003986:0.004563:0.005492:0.009772:0.002352:0.003986:0.007173:0.005492:0.003986:0.006303:0.008020:0.007644:0.005492:0.006515:0.005492:0.008055:0.002352:0.008032:0.008020:0.007644:0.003986:0.007644:0.004563:0.003257:0.003257
N Engl J Med.:@0.804629:0.615292:0.888978:0.615292:0.888978:0.603017:0.804629:0.603017:0.008702:0.005492:0.006303:0.007173:0.007914:0.002352:0.005492:0.005668:0.005492:0.010807:0.007644:0.008055:0.003257
 2016; :@0.888978:0.615292:0.927043:0.615292:0.927043:0.603017:0.888978:0.603017:0.005492:0.006515:0.006515:0.006515:0.006515:0.003257:0.003257
375:1834-1844 :@0.544232:0.626193:0.626312:0.626193:0.626312:0.613918:0.544232:0.613918:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.006515:0.006515:0.003257
18.  Holman R, Bethel MA, Mentz RJ, :@0.519032:0.637095:0.734297:0.637095:0.734297:0.624820:0.519032:0.624820:0.006515:0.006515:0.003257:0.003257:0.005656:0.008032:0.007702:0.002352:0.011030:0.008032:0.007173:0.004621:0.007138:0.003257:0.004621:0.006750:0.007644:0.003986:0.007173:0.007644:0.002352:0.004621:0.010807:0.008702:0.003257:0.004621:0.010807:0.007644:0.007173:0.003986:0.004998:0.004621:0.007138:0.005668:0.003257:0.003257
et al.:@0.735673:0.637095:0.765565:0.637095:0.765565:0.624820:0.735673:0.624820:0.007644:0.003986:0.004621:0.008032:0.002352:0.003257
 Effects of once-weekly ex-:@0.765565:0.637095:0.923774:0.637095:0.923774:0.624820:0.765565:0.624820:0.004621:0.006303:0.003692:0.003692:0.007644:0.007608:0.003986:0.004563:0.004621:0.007702:0.003692:0.004621:0.007702:0.007173:0.007608:0.007644:0.003904:0.009772:0.007644:0.007644:0.005903:0.002352:0.006303:0.004621:0.007644:0.005644:0.003904
enatide on cardiovascular outcomes in type 2 diabetes. :@0.544232:0.647996:0.875843:0.647996:0.875843:0.635721:0.544232:0.635721:0.007644:0.007173:0.008032:0.003986:0.002352:0.008055:0.007644:0.004363:0.007702:0.007173:0.004363:0.007608:0.008032:0.003540:0.008055:0.002352:0.007702:0.006515:0.008032:0.004563:0.007608:0.007150:0.002352:0.008032:0.003540:0.004374:0.007702:0.007150:0.003986:0.007608:0.007702:0.011030:0.007644:0.004563:0.004363:0.002352:0.007173:0.004374:0.003986:0.006303:0.008020:0.007644:0.004374:0.006515:0.004374:0.008055:0.002352:0.008032:0.008020:0.007644:0.003986:0.007644:0.004563:0.003257:0.003257
N Engl J :@0.876960:0.647996:0.927066:0.647996:0.927066:0.635721:0.876960:0.635721:0.008702:0.004363:0.006303:0.007173:0.007914:0.002352:0.004374:0.005668:0.003257
Med. :@0.544232:0.658898:0.577252:0.658898:0.577252:0.646622:0.544232:0.646622:0.010807:0.007644:0.008055:0.003257:0.003257
2017;377:1228-1239:@0.577252:0.658898:0.685390:0.658898:0.685390:0.646622:0.577252:0.646622:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.006515:0.006515
19.  Davies MJ, D’Alessio DA, Fradkin J, :@0.519032:0.669799:0.749878:0.669799:0.749878:0.657524:0.519032:0.657524:0.006515:0.006515:0.003257:0.003257:0.005656:0.008749:0.008032:0.006515:0.002352:0.007644:0.004563:0.004739:0.010807:0.005668:0.003257:0.004727:0.008749:0.004127:0.008702:0.002352:0.007644:0.004563:0.004563:0.002352:0.007702:0.004739:0.008749:0.008702:0.003257:0.004727:0.005703:0.003540:0.008032:0.008055:0.005903:0.002352:0.007173:0.004727:0.005668:0.003257:0.003257
et al. :@0.751348:0.669799:0.784603:0.669799:0.784603:0.657524:0.751348:0.657524:0.007644:0.003986:0.004727:0.008032:0.002352:0.003257:0.003257
Management of Hyper-:@0.786073:0.669799:0.923797:0.669799:0.923797:0.657524:0.786073:0.657524:0.010807:0.008032:0.007173:0.008032:0.007914:0.007644:0.011030:0.007644:0.007173:0.003986:0.004727:0.007702:0.003692:0.004727:0.008032:0.006303:0.008020:0.007644:0.003540:0.003904
glycemia in Type 2 Diabetes, 2018. A  consensus report  by the :@0.544232:0.680701:0.927055:0.680701:0.927055:0.668425:0.544232:0.668425:0.007914:0.002352:0.006303:0.007608:0.007644:0.011030:0.002352:0.008032:0.006538:0.002352:0.007173:0.006538:0.005009:0.006303:0.008020:0.007644:0.006538:0.006515:0.006538:0.008749:0.002352:0.008032:0.008020:0.007644:0.003986:0.007644:0.004563:0.003257:0.006538:0.006515:0.006515:0.006515:0.006515:0.003257:0.006538:0.008702:0.003257:0.003269:0.007608:0.007702:0.007173:0.004563:0.007644:0.007173:0.004563:0.007150:0.004563:0.006538:0.003540:0.007644:0.008020:0.007702:0.003540:0.003986:0.003257:0.003269:0.008020:0.006303:0.006538:0.003986:0.007173:0.007644:0.003257
American Diabetes Association (ADA) and the European Associa-:@0.544232:0.691602:0.923785:0.691602:0.923785:0.679327:0.544232:0.679327:0.008702:0.011030:0.007644:0.003540:0.002352:0.007608:0.008032:0.007173:0.003975:0.008749:0.002352:0.008032:0.008020:0.007644:0.003986:0.007644:0.004563:0.003986:0.008702:0.004563:0.004563:0.007702:0.007608:0.002352:0.008032:0.003986:0.002352:0.007702:0.007173:0.003986:0.004339:0.008702:0.008749:0.008702:0.004339:0.003986:0.008032:0.007173:0.008055:0.003986:0.003986:0.007173:0.007644:0.003975:0.006303:0.007150:0.003540:0.007702:0.008020:0.007644:0.008032:0.007173:0.003975:0.008702:0.004563:0.004563:0.007702:0.007608:0.002352:0.008032:0.003904
tion  for  the  study of  Diabetes (EAsD). :@0.544232:0.702504:0.769504:0.702504:0.769504:0.690228:0.544232:0.690228:0.003986:0.002352:0.007702:0.007173:0.003257:0.002034:0.003692:0.007702:0.003540:0.003257:0.002034:0.003986:0.007173:0.007644:0.003257:0.002046:0.005856:0.003986:0.007150:0.008055:0.006303:0.005303:0.007702:0.003692:0.003257:0.002034:0.008749:0.002352:0.008032:0.008020:0.007644:0.003986:0.007644:0.004563:0.005303:0.004339:0.006303:0.008702:0.005856:0.008749:0.004339:0.003257:0.003257
Diabetes Care.:@0.771550:0.702504:0.859874:0.702504:0.859874:0.690228:0.771550:0.690228:0.008749:0.002352:0.008032:0.008020:0.007644:0.003986:0.007644:0.004563:0.005303:0.009560:0.008032:0.003540:0.007644:0.003257
 2018 Dec; :@0.859874:0.702504:0.927055:0.702504:0.927055:0.690228:0.859874:0.690228:0.005303:0.006515:0.006515:0.006515:0.006515:0.005303:0.008749:0.007644:0.007608:0.003257:0.003257
41(12):2669-2701. https://doi.org/10.2337/dci18-0033:@0.544232:0.713405:0.840201:0.713405:0.840201:0.701130:0.544232:0.701130:0.006515:0.006515:0.004339:0.006515:0.006515:0.004339:0.003257:0.006515:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.006515:0.006515:0.003257:0.003281:0.007173:0.003986:0.003986:0.008020:0.004563:0.003257:0.005139:0.005139:0.008055:0.007702:0.002352:0.003257:0.007702:0.003540:0.007914:0.005139:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.006515:0.005139:0.008055:0.007608:0.002352:0.006515:0.006515:0.003904:0.006515:0.006515:0.006515:0.006515
figure 10. exenatide er vs. placebo outcomes:@0.182563:0.453386:0.518206:0.453386:0.518206:0.436887:0.182563:0.436887:0.007257:0.003629:0.009979:0.009071:0.004838:0.009676:0.004233:0.008467:0.008467:0.004233:0.004233:0.007862:0.008467:0.009676:0.009071:0.009979:0.004536:0.003629:0.009979:0.009676:0.004233:0.007862:0.008769:0.004233:0.008467:0.006652:0.004233:0.004233:0.009979:0.003629:0.009979:0.009676:0.009676:0.009979:0.009676:0.004233:0.009676:0.009071:0.004536:0.009676:0.009676:0.014212:0.009676:0.006652
Holman RR, Bethel MA, Mentz RJ, :@0.182563:0.436435:0.317509:0.436435:0.317509:0.427666:0.182563:0.427666:0.005703:0.005468:0.001646:0.007845:0.005703:0.005090:0.002293:0.005065:0.005065:0.002293:0.002293:0.004788:0.005426:0.002814:0.005090:0.005426:0.001646:0.002293:0.007686:0.006182:0.002293:0.002293:0.007686:0.005426:0.005090:0.002814:0.003536:0.002293:0.005065:0.004015:0.002293:0.002327
et al:@0.317476:0.436435:0.335392:0.436435:0.335392:0.427666:0.317476:0.427666:0.005426:0.002814:0.002293:0.005703:0.001680
. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. :@0.335358:0.436435:0.672588:0.436435:0.672588:0.427666:0.335358:0.427666:0.002293:0.002293:0.004469:0.002604:0.002604:0.005426:0.005401:0.002814:0.003225:0.002293:0.005468:0.002604:0.002293:0.005468:0.005090:0.005401:0.005426:0.002755:0.006946:0.005426:0.005426:0.004183:0.001646:0.004469:0.002293:0.005426:0.003998:0.005426:0.005090:0.005703:0.002814:0.001646:0.005720:0.005426:0.002293:0.005468:0.005090:0.002293:0.005401:0.005703:0.002495:0.005720:0.001646:0.005468:0.004620:0.005703:0.003225:0.005401:0.005073:0.001646:0.005703:0.002495:0.002293:0.005468:0.005073:0.002814:0.005401:0.005468:0.007845:0.005426:0.003225:0.002293:0.001646:0.005090:0.002293:0.002814:0.004469:0.005695:0.005426:0.002293:0.004620:0.002293:0.005720:0.001646:0.005703:0.005695:0.005426:0.002814:0.005426:0.003225:0.002293:0.002327
N Engl J Med:@0.672555:0.436435:0.725690:0.436435:0.725690:0.427666:0.672555:0.427666:0.006216:0.002327:0.004502:0.005124:0.005653:0.001680:0.002327:0.004049:0.002327:0.007719:0.005460:0.005754
. 2017; 377:1228-1239:@0.725639:0.436435:0.809861:0.436435:0.809861:0.427666:0.725639:0.427666:0.002327:0.002327:0.004653:0.004653:0.004653:0.004653:0.002327:0.002327:0.004653:0.004653:0.004653:0.002327:0.004653:0.004653:0.004653:0.004653:0.002789:0.004653:0.004653:0.004653:0.004653